Esmya (ulipristal acetate)
/ ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
473
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
March 06, 2025
Uses of ulipristal acetate beyond emergency contraception: a narrative review.
(PubMed, Contraception)
- "Access to UPA is crucial not only for EC but for the treatment of many other gynecologic and non-gynecologic conditions."
Journal • Review • Breast Cancer • Hepatology • Hormone Receptor Breast Cancer • Liver Failure • Novel Coronavirus Disease • Oncology • Solid Tumor • Uterine Leiomyoma • Women's Health
January 23, 2025
A Proof-of-Concept Study of Ulipristal Acetate for Early Medication Abortion.
(PubMed, NEJM Evid)
- "This study suggests that ulipristal acetate followed by misoprostol is an effective and acceptable medication abortion regimen with no reported serious adverse events. (This project is supported by the OPTions Initiative. The study registered as ISRCTN35625202.)."
Journal
January 18, 2025
Progesterone signaling in uterine fibroids: Molecular mechanisms and therapeutic opportunities.
(PubMed, Life Sci)
- "Clinical trials have demonstrated the effectiveness of SPRMs like mifepristone, asoprisnil, and ulipristal acetate in reducing fibroid size and symptoms, though concerns about safety, particularly with long-term use, remain. Newer SPRMs, such as vilaprisan, show promise, but further research is necessary to assess the long-term safety and effectiveness. This review discusses the mechanisms by which progesterone contributes to fibroid growth and examines clinical effectiveness of SPRMs as potential treatments for uterine fibroids."
Journal • Review • Gynecology • Oncology • Solid Tumor • Uterine Leiomyoma • Women's Health • PGR
January 15, 2025
Selective progesterone receptor modulators for the treatment of dysmenorrhea: an update.
(PubMed, Expert Opin Pharmacother)
- "The present review examines the development of the clinical trials and observational studies done with the different SPRMs for the treatment of dysmenorrhea in patients with uterine diseases. Mifepristone, telapristone acetate and vilaprisan have antagonistic activity on PRs, while ulipristal acetate and asoprisnil have both potent antagonist and partial agonist effects.While no studies have been done on primary dysmenorrhea, the different SPRMs have been studied in the treatment of endometriosis, adenomyosis and uterine fibroid-related dysmenorrhea."
Journal • Review • Endometriosis • Gynecology • Pain • Solid Tumor • Uterine Leiomyoma • Women's Health
January 23, 2025
New Data on Ulipristal Acetate and Misoprostol for Medication Abortion - A Step Forward?
(PubMed, NEJM Evid)
- No abstract available
Journal
December 11, 2024
Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception
(clinicaltrials.gov)
- P3 | N=980 | Not yet recruiting | Sponsor: The University of Hong Kong
New P3 trial
October 30, 2024
Current and future management of uterine fibroids – a pilot survey of UK gynaecologists
(ESGE 2024)
- "The newer GnRH- antagonists were available at 75.9% hospitals, whilst 1.9% reported that they had access to Esmya.Just 9% of respondents would not offer myomectomy to a woman whose family was complete.15% surgeons reported that they routinely hysteroscope their patients at the time of myomectomy...Over 50% respondents were female, representing a change in the gynaecology workforce.The results of this work are limited by the small sample size. We intend to edit the questionnaire and repeat the survey to encourage better participation."
Gynecologic Cancers • Gynecology • Oncology • Solid Tumor • Uterine Leiomyoma • Women's Health
October 29, 2024
Promising selective progesterone receptor modulators: what's new in female contraception?
(PubMed, Expert Opin Investig Drugs)
- "Selective progesterone receptor modulators (SPRMs), such as mifepristone and ulipristal acetate (UPA), have demonstrated high efficacy and safety as single dose treatments for medication abortion and emergency contraception (EC). However, current restrictions on UPA limit longer term use. Perhaps other SPRMs without hepatic impacts may emerge to fill this need."
Journal • Review • Hepatology • Liver Failure • Obstetrics
October 26, 2024
White matter integrity upon progesterone antagonism in individuals with premenstrual dysphoric disorder: A randomized placebo-controlled diffusion tensor imaging study.
(PubMed, Prog Neuropsychopharmacol Biol Psychiatry)
- P2 | "The main findings suggest that SPRM treatment did not impact white matter microstructure compared with placebo. However, secondary exploratory analyses yielded between-group differences after treatment, which call for further investigation on the tracts potentially impacted by progesterone antagonism."
Clinical • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry
October 20, 2024
Dual Au/Ag Catalyzed Regiospecific Intramolecular Hydroacyloxylation and Hydroalkoxylation of Unactivated Geminal-Substituted Olefins.
(PubMed, Chem Asian J)
- "This method has been effectively applied for late-state functionalization to produce bioactive natural products such as rumphellaone A, mycophenolate, and (-)-ambrox. The successful gram-scale synthesis of the anticonvulsant, hypnotic drug (±)-ethyl phenyl butyro lactone (EPBL), (±)-Boivinianin A and the ability to synthesize challenging spiro and bicyclic lactone underscores the synthetic potential of this methodology. Mechanistic insights into gold-silver catalyzed lactonization of olefins have also been discussed."
Journal
September 20, 2024
Impact of Regulatory Interventions on Ulipristal Acetate 5 mg (Esmya) Use in Spain: An Interrupted Time-Series Analysis.
(PubMed, Pharmacoepidemiol Drug Saf)
- "Despite RMM had an immediate strong impact on UPA use, the last segment upward trend in the long-term might have been affected by the lack of comparable therapeutic alternatives. Further studies should be performed to confirm the increase trend observed and analyze subsequent measures and additional data."
Journal • Hepatology • Liver Failure
September 19, 2024
Premenstrual Dysphoric Disorder: a systematic review of treatments with antidepressants and contraceptives
(NAMS 2024)
- "RoB2 tool used for risk of bias anaylsis Seventeen placebo-controlled RCTs with antidepressants were identified: seven with sertraline, three with fluoxetine, one with venlafaxine, five with paroxetine, and 1 with escitalopram...Six studies with contraceptives were found: one with levonorgestrel and ethinyl estradiol, one with ulipristal acetate, and 4 with drospirenone and ethinyl estradiol... Antidepressants have the most and best quality evidence for use in PMDD. Their effect appears to emerge quickly and at lower doses than those commonly used for depression or anxiety, allowing for intermittent use, during luteal phase. Use only during symptomatic phase showed uncertain results, requiring further clarification."
Review • CNS Disorders • Depression • Mood Disorders • Psychiatry
September 12, 2024
Is there still a place for progesterone receptor modulators in chronic use ?
(PubMed, Rev Med Liege)
- "First identified with mifepristone, they are now represented by ulipristal acetate (UPA), used for emergency contraception and uterine fibroids. Despite certain concerns, SPRMs offer promising prospects in gynecological pathologies, opening up new therapeutic avenues to improve women's health and quality of life. This article describes the case of a patient with peritoneal leiomyomatosis for whom UPA significantly alleviated symptoms, reduced disease progression and improved quality of life, even allowing a pregnancy."
Journal • Breast Cancer • Endometriosis • Gynecology • Hepatitis C • Hormone Receptor Breast Cancer • Liver Failure • Oncology • Solid Tumor • Uterine Leiomyoma • Women's Health
September 08, 2024
Hormonal methods for emergency contraception.
(PubMed, Best Pract Res Clin Obstet Gynaecol)
- "Ulipristal acetate (UPA) and levonorgestrel (LNG) are the recommended oral methods...Mifepristone can also be used for EC but its availability is limited to few countries...Hormonal contraception can be quickstarted immediately following LNG, or five days following UPA. LNG-releasing intrauterine devices and cyclo-oxygenase inhibitors are promising options for EC to be further studied."
Journal • Review • Long-acting Reversible Contraceptives
August 19, 2024
Role of inflammation and immune response in the pathogenesis of uterine fibroids: Including their negative impact on reproductive outcomes.
(PubMed, J Reprod Immunol)
- "Hormonal treatments using gonadotropin releasing hormone analogs and the selective progesterone receptor modulator ulipristal acetate significantly shrink UFs and improve UF-related symptoms. These compounds can regulate local inflammation in UFs and adjacent myometrium. Controlling and improving local inflammation caused by UFs may represent a novel therapeutic strategy for UFs and potentially improve reproductive outcomes in women with symptomatic UFs."
Journal • Review • Gynecology • Hematological Disorders • Inflammation • Oncology • Solid Tumor • Uterine Leiomyoma • Women's Health • IL10 • IL6 • PGR • TGFB1 • TNFA
July 15, 2024
Double dosing ulipristal acetate emergency contraception for individuals with obesity: a randomised crossover trial.
(PubMed, BMJ Sex Reprod Health)
- "A standard 30 mg dose of UPA is sufficient to delay ovulation regardless of BMI or weight. Results of our study do not support dose adjustment for body size."
Journal • Genetic Disorders • Obesity
July 12, 2024
Ovarian Function With ENG Implant and UPA Use
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: University of Utah | Active, not recruiting ➔ Completed
Trial completion • Long-acting Reversible Contraceptives
June 26, 2024
Safety of Progestogen Hormonal Contraceptive Methods during Lactation: An Overview.
(PubMed, Clin Pract)
- "Based on published scientific reports, progestogen hormonal contraceptives can be considered a relatively safe solution for women desiring to continue feeding their infant with their milk while using hormonal contraception. It is important to seek guidance on selecting the best contraception method based on the latest medical knowledge, tailored to the individual needs and clinical circumstances of each woman and place of residence. A woman should always be informed of the potential risks of such a treatment and then allowed to make her own decision based on the knowledge received from a specialist."
Journal • Review
June 20, 2024
In Vitro Human Endometrial Cells and In Vivo Rat Model Studies Suggest That Ulipristal Acetate Impacts Endometrial Compatibility for Embryo Implantation.
(PubMed, Arch Med Res)
- "These results support that UPA as an emergency contraceptive might have post-fertilization effects that may affect embryo implantation."
Journal • Preclinical
June 17, 2024
Emergency contraception - A narrative review of literature.
(PubMed, Eur J Obstet Gynecol Reprod Biol)
- "Taking emergency contraception can result in various adverse effects, therefore it should be introduced after thorough analysis of woman's medical history, including gynecological and obstetric history and potential contraindications. Additionally, the patient should receive detailed information about the drug mechanism of efficacy and potential adverse effects."
Journal • Review • Long-acting Reversible Contraceptives • Obstetrics
June 05, 2024
Advancements and Emerging Therapies in the Medical Management of Uterine Fibroids: A Comprehensive Scoping Review.
(PubMed, Med Sci Monit)
- "While existing treatments offer symptomatic relief and preparation for surgery, our findings point to a significant need for further research into long-term solutions, especially owing to recent limitations in the use of ulipristal acetate due to risk of liver damage. Initial studies involving vitamin D and epigallocatechin gallate are encouraging; however, additional research is required to establish definitive therapeutic roles."
Journal • Review • Gynecology • Oncology • Solid Tumor • Uterine Leiomyoma • Women's Health
May 20, 2024
Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)
(clinicaltrials.gov)
- P=N/A | N=30 | Terminated | Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | N=60 ➔ 30 | Unknown status ➔ Terminated; Lack of recruitment
Enrollment change • Trial termination • Gynecology • Hepatology • Liver Failure • Solid Tumor • Uterine Leiomyoma • Women's Health
May 15, 2024
Ulipristal for Endometriosis-related Pelvic Pain
(clinicaltrials.gov)
- P4 | N=1 | Completed | Sponsor: Northwestern University | Unknown status ➔ Completed | N=25 ➔ 1
Enrollment change • Trial completion • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health
May 11, 2024
Advances in uterine fibroid research: Linking progesterone and the TGF-β signaling pathway.
(PubMed, Fertil Steril)
- No abstract available
Journal • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health • TGFB1
May 09, 2024
Pharmacist recommendations for emergency contraception in Belgium: a simulated user study.
(PubMed, Eur J Contracept Reprod Health Care)
- "We considered the following responses as adequate: Prescribing ulipristal acetate or redirecting to another pharmacy, in case of unavailability, or referring for a copper IUD...More than one-third of visited pharmacies did not distribute appropriate emergency contraception, underlining the need for improvement. We hypothesise that this may be achieved with appropriate training, use a dispensing checklist."
Journal • Long-acting Reversible Contraceptives
1 to 25
Of
473
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19